Highest-materiality recent filing
Nephros Q1 net revenue up 7% to $5.2M; net income falls to $140K; tariffs hit margins
Net revenue $5.2M (+7% YoY); programmatic revenue up 23% YoY.
Nephros posts updated 2026 corporate presentation; no material new details disclosed
Filing includes an updated corporate presentation posted on company website on March 27, 2026.
Replaces prior Dec 2023 License & Supply Agreement with Medica; that agreement terminated.
Net revenue $4.4M, up 36% YoY from $3.3M; net income $237k vs net loss $289k.
Nephros shareholders elect Lisa Nettis to board, ratify auditor, approve exec comp at annual meeting
Lisa Nettis elected to three-year term with 6,066,124 votes for, 84,178 withheld.
Nephros Q1 2025 revenue $4.9M (+38% YoY), net income $558K, adjusted EBITDA $667K
Net revenue $4.9M, up 38% from $3.5M in Q1 2024; core programmatic revenue grew 23%.
Director Alisa Lask will not stand for re-election at Nephros annual meeting on June 16, 2025
Alisa Lask notified the board on April 23, 2025, that she will not stand for re-election.
Nephros posts updated 2024 corporate presentation on website; no material changes disclosed
Filing announces posting of updated corporate presentation on company website.
Nephros reports first annual net income; Q4 revenue up 19% YoY to $3.9M
Net income of $74K for FY2024 vs net loss of $1.6M in 2023; first annual profit in company history.
Nephros CFO Krandel gets two stock options, bonus target raised to 30%
Amendment to CFO Judith Krandel's letter agreement grants options for 54,359 and 58,961 shares under 2024 Equity Incentive Plan.
Nephros posts Q3 net income of $0.2M, first profitable quarter; revenue $3.5M
Net revenue $3.5M, down 6% YoY but up 8% from Q2 2024.
Nephros posts updated 2024 corporate presentation; no financial details in filing
Updated 2024 Corporate Presentation made available on company website on August 26, 2024.
Nephros stockholders approve 2024 Equity Incentive Plan authorizing 2,616,875 shares
Plan adds 900,000 new shares plus prior plan reserve and returning shares; total shares authorized 2,616,875.
Nephros Q1 revenue down 5% to $3.5M; net loss narrows to $0.2M
Net revenue $3.5M, down 5% YoY, but programmatic (recurring non-ER) business grew 12% YoY.
Nephros furnishes corporate presentation at MicroCap showcase; no material new info
Filing indicates presentation at Planet MicroCap Showcase: VEGAS 2024 on May 1, 2024.
Nephros FY2023 revenue up 43% to $14.2M; net loss narrows to $1.6M from $4.3M
Full-year net revenue from continuing ops $14.2M, up 43% YoY; Q4 revenue $3.3M, up 27%.
On April 23, 2025, Alisa Lask notified the Board of Directors (the “Board”) of Nephros, Inc. (the “Company”) that she will not stand for re-election to the Board at the Company’s annual meeting of stockholders scheduled to be held on June 16, 2025 (the “2025 Annual Meeting”).
Max materiality 0.75 · Median 0.55 · Most common event earnings